Literature DB >> 16377830

Approach to neuromuscular disorders in the intensive care unit.

Kenneth C Gorson1.   

Abstract

Neuromuscular disorders increasingly are recognized as a complication in patients in the intensive care unit (ICU) and represent a common cause of prolonged ventilator dependency. The distinct syndromes of critical illness myopathy, prolonged neuromuscular blockade, and critical illness polyneuropathy (CIP) may arise as a consequence of sepsis, multi-organ failure, and exposure to various medications--notably, intravenous corticosteroids and neuromuscular blocking agents--but the pathophysiology of these disorders remains poorly understood. More than one syndrome may occur simultaneously, and the distinctions may be difficult in a particular patient, but a specific diagnosis usually can be established after careful clinical, electrodiagnostic, and, when necessary, histological evaluation. For example, asthmatics requiring treatment with corticosteroids and neuromuscular blocking agents may develop an acute myopathy characterized by generalized weakness, preserved eye movements, elevated creatine kinase levels, and myopathic motor units on electromyography (EMG). Muscle biopsy demonstrates distinctive features of thick (myosin) filament loss on ultrastructural studies. Conversely, those with a prolonged ICU course that is complicated by episodes of sepsis with failure to wean from the ventilator, distal or generalized flaccid limb weakness, and areflexia probably have CIP. EMG in these patients demonstrates reduced or absent motor and sensory potentials with neurogenic motor units. Prolonged neuromuscular blockade most commonly occurs in patients with renal failure who have received prolonged infusions of neuromuscular blockers. There is severe flaccid, areflexic paralysis with normal sensation, facial weakness, and ophthalmoparesis that persists for days or weeks after the neuromuscular blockers have been discontinued. Repetitive nerve stimulation shows a decrement of the compound muscle action potential and, in most cases, establishes a disorder of neuromuscular transmission. With the recent epidemic of West Nile virus infection, a clinical syndrome of acute flaccid paralysis with several features indistinguishable from poliomyelitis has emerged. This article critically examines the clinical, electrophysiological, and pathological features of these and other acute neuromuscular syndromes that arise in the context of ICU care and summarizes the current understanding of the pathophysiology and treatment of these disorders.

Entities:  

Mesh:

Year:  2005        PMID: 16377830      PMCID: PMC7101970          DOI: 10.1385/NCC:3:3:195

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  209 in total

1.  Critical illness myopathy.

Authors:  D Lacomis; D W Zochodne; S J Bird
Journal:  Muscle Nerve       Date:  2000-12       Impact factor: 3.217

2.  Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy.

Authors:  E F Wijdicks; J R Fulgham
Journal:  Muscle Nerve       Date:  1994-12       Impact factor: 3.217

3.  Prolonged ventilation in acute severe asthma caused by the Guillain-Barre-Strohl syndrome.

Authors:  A B Millar; S W Clarke; S N Davis; M L Gross
Journal:  J R Soc Med       Date:  1984-11       Impact factor: 5.344

4.  Risk factors for hydrocortisone myopathy in acute severe asthma.

Authors:  C D Shee
Journal:  Respir Med       Date:  1990-05       Impact factor: 3.415

5.  Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis.

Authors:  M Mohr; L Englisch; A Roth; H Burchardi; S Zielmann
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

6.  The effect of prednisolone on neuromuscular transmission in the rat diaphragm.

Authors:  H Van Wilgenburg
Journal:  Eur J Pharmacol       Date:  1979-05-15       Impact factor: 4.432

7.  Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure.

Authors:  M W Nicolle; D J Stewart; H Remtulla; R Chen; C F Bolton
Journal:  Muscle Nerve       Date:  1996-10       Impact factor: 3.217

Review 8.  Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure.

Authors:  E F Hund
Journal:  J Neurol Sci       Date:  1996-03       Impact factor: 3.181

Review 9.  Rehabilitation of patients with quadriparesis after treatment of status asthmaticus with neuromuscular blocking agents and high-dose corticosteroids.

Authors:  S Apte-Kakade
Journal:  Arch Phys Med Rehabil       Date:  1991-11       Impact factor: 3.966

10.  Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey.

Authors:  J H Hansen-Flaschen; S Brazinsky; C Basile; P N Lanken
Journal:  JAMA       Date:  1991-11-27       Impact factor: 56.272

View more
  5 in total

Review 1.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 2.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

Review 3.  Neurology of Sepsis.

Authors:  Rochelle Sweis; Jorge Ortiz; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

4.  Exploring the Muscle Metabolomics in the Mouse Model of Sepsis-Induced Acquired Weakness.

Authors:  Yikang Jiang; Qiang Wei; Wei Liu; Qiunan Chen; Xia Chen; Zhongzhen Yuan; Na Luo; Xi Chen; Chuanjiang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-16       Impact factor: 2.650

Review 5.  Management of intracerebral hemorrhage--use of statins.

Authors:  Edward T Van Matre; Deb S Sherman; Tyree H Kiser
Journal:  Vasc Health Risk Manag       Date:  2016-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.